HOTH Stock Summary and Trading Ideas (Hoth Therapeutics | NASDAQ:HOTH)

Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA). Its current assets are focused in treating cancer, skin toxicities, Alzheimer's, and weight loss.

Hoth Therapeutics trades on the NASDAQ stock market under the symbol HOTH.

As of April 10, 2026, HOTH stock price declined to $0.52 with 348,852 million shares trading.

HOTH has a beta of 0.53, meaning it tends to be less sensitive to market movements. HOTH has a correlation of 0.01 to the broad based SPY ETF.

HOTH has a market cap of $9.86 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, HOTH traded as high as $4.30 and as low as $.50.

The top ETF exchange traded funds that HOTH belongs to (by Net Assets): VXF.

HOTH has underperformed the market in the last year with a price return of -35.9% while the SPY ETF gained +30.9%. HOTH has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -52.3% and -36.0%, respectively, while the SPY returned -1.8% and +7.2%, respectively.

HOTH support price is $.51 and resistance is $.57 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HOTH shares will trade within this expected range on the day.